West Virginia University Logo

NIH Funding Opportunities

NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional)
(RFA-DK-20-002) National Institute of Diabetes and Digestive and Kidney Diseases

This Funding Opportunity Announcement (FOA) invites applications that propose a Center for Diabetes Translation Research (CDTR) to advance research along the spectrum of diabetes T2-T4 translational research (i.e., bedside to clinical practice and community settings, dissemination and implementation). The purpose of this Centers program is to accelerate innovation of diabetes translation to maximize positive impacts of research on population health through activities and core services that offer specialized expertise, tools, education, and support. An emphasis on novel methods and research to address health equity and reduce diabetes-related health disparities is encouraged.
Application Receipt Date(s): October 20, 2020

Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional)
(RFA-HD-21-006) Eunice Kennedy Shriver National Institute of Child Health and Human Development

The purpose of this FOA is to invite applications to address priority gaps in our understanding of the role of nutrition in the care and development of preterm infants. Significant gaps exist in our understanding of: (1) nutrient needs of infants across this developmental period; (2) factors to be considered in the transitioning of infants from parenteral to enteral feeding; (3) specific needs of infants currently cared for in Neonatal Intensive Care Units (NICUs); and (4) other standards (e.g., growth standards, intrauterine accretion rates for essential and non-essential nutrients and other required bioactive substances, biomarkers for assessing nutritional status, etc.) to support the establishment of standards of nutritional care for preterm infants.
Application Receipt Date(s): November 30, 2020

NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
(RFA-RM-20-011) Office of Strategic Coordination (Common Fund)

The NIH Director's Pioneer Award supports individual scientists of exceptional creativity who propose highly innovative and broadly impactful research towards the ultimate goal of enhancing human health.
Application Receipt Date(s): September 11, 2020. No late applications will be accepted for this Funding Opportunity Announcement.

NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional)
(RFA-RM-20-012) Office of Strategic Coordination (Common Fund)

The NIH Director’s New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH.
Application Receipt Date(s): August 21, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
(RFA-RM-20-013) Office of Strategic Coordination (Common Fund)

The NIH Director’s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies.
Application Receipt Date(s): September 30, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)
(RFA-RM-20-014) Office of Strategic Coordination (Common Fund)

The NIH Director's Early Independence Award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.

Application Receipt Date(s): September 4, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

PAR-19-242Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)

National Cancer Institute

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers.

Application Receipt Date(s): June 17, 2020; June 17, 2021 *See (NOT-CA-20-069) for Notice of Change: Late Application Policy for June 17, 2020, Application Due Date of PAR-19-242, Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) Due to Public Health Emergency for US Coronavirus Disease 2019

Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions (NOT-OD-20-106)
Office of Behavioral and Social Sciences Research, National Center for Complementary and Integrative Health, National Cancer Institute, National Institute on Aging, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute on Drug Abuse, National Institute of Dental and Craniofacial Research, National Institute of Mental Health, National Institute of Nursing Research

The Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Notice to highlight interest in the systematic development of novel health-related behavioral interventions that leverage new, emerging or understudied areas in basic behavioral and social sciences research (bBSSR). To achieve more potent and sustained strategies to promote health-related behavior change, there is a need for intentional and methodical translation of foundational behavioral and social science discoveries into new or improved interventions. This includes research that focuses on use-inspired bBSSR, understanding of mechanisms of action underlying initial and sustained behavior change, and systematic development and testing of health-related behavioral interventions and their components.

Application due dates vary depending on Institute and FOA; please see FOA for specific due dates for submission of proposals.

Related Announcements to Apply under:

  • PAR-19-213 - Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)
  • PAR-19-212 - Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)
  • PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)
  • PA-18-850 - Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)
  • PA-18-722 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)
  • PA-18-723 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)
  • PAR-18-581 - Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 - Clinical Trial Optional)
  • PAR-18-877 - Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)
  • PAR-20-070 - Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)
  • PAR-19-070 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
  • PA-20-184- NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  • PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)
  • PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
  • PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
  • PAR-18-069 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
  • PAR-19-309 - Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)
  • PAR-18-559 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
  • PAR-18-307 - Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)
  • PAR-18-892 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)
  • PAR-18-893 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)
  • PAR-18-656 - NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  • PA-18-932 - Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)
  • PAR-18-612 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 Clinical Trial Optional)
  • PAR-18-611 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 Clinical Trial Optional)
  • PA-18-729 - Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional)
  • PA-18-728 - Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)
  • PAR-19-274 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
  • PAR-19-275 - Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
  • PAR-17-491 - Implementing the Most Successful Interventions to Improve HIV/AIDS Outcomes in U.S. Communities (R01 Clinical Trial Optional)
  • PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)
  • PA-18-945 - Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)
  • PA-18-944 - Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)
  • PA-18-943 - Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)
  • PAR-19-045 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)
  • PAR-19-044 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)
  • PAR-19-057 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)
  • PAR-19-058 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)
  • PAR-19-136 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)
  • PAR-19-153 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)
  • PAR-19-321- Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)
  • PAR-19-320 - Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)
  • PAR-18-595 - Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)
  • PA-18-592 - Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)
  • RFA-MH-18-704 - Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 - Clinical Trial Required)
  • RFA-MH-18-705- Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 - Clinical Trial Required)
  • RFA-MH-18-706 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 - Clinical Trial Required)
  • PA-20-141 - Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 - Clinical Trial Optional)
  • PA-18-322 - Fundamental Science Research on Mind and Body Approaches (R21 Clinical Trial Optional)
  • PA-18-323 - Fundamental Science Research on Mind and Body Approaches (R01 Clinical Trial Optional)

National Institutes of Health, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.  The objective of the NIH Mentored Clinical Scientist Research Career Development Award (K08) is to provide salary and research support for a sustained period of "protected time" (3-5 years) to support didactic study and/or mentored research for individuals with clinical doctoral degrees.

Application Receipt Date(s): Standard dates apply. The first standard application due date for this FOA is June 12, 2020.

National Institutes of Health, National Center for Complementary and Integrative Health, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research
The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.

Application Receipt Date(s): Standard dates apply. The first standard application due date for this FOA is June 12, 2020

PA-20-190, Mentored Research Scientist Development Award (Parent K01, Independent Clinical Trial Not Allowed)

National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Allergy and Infectious Diseases (NIAID), Office of Research Infrastructure Programs (ORIP)

The objective of the NIH Mentored Research Scientist Development Award (K01) is to provide salary and research support for a sustained period of “protected time” (3-5 years) for intensive research career development, under the guidance of an experienced mentor, or sponsor in the biomedical, behavioral or clinical sciences leading to research independence.

Standard due dates apply.  The first standard application due date for this FOA is June 12, 2020.

  • PA-20-197 Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)
  • PA-20-198 Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required), and
  • PA-20-199, Mentored Quantitative Research Development Award (Parent K25, Independent Clinical Trial Not Allowed)

National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences ( NIGMS), National Cancer Institute (NCI)

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease.  The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

Standard due dates apply.  The first standard application due date for this FOA is June 12, 2020.

PA-20-186, Midcareer Investigator Award in Patient-Oriented Research (Parent K24, Independent Clinical Trial Not Allowed)

National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH)

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty.

Standard due dates apply.  The first standard application due date for this FOA is June 12, 2020.

NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)
(PAR-20-210) National Institute of Allergy and Infectious Diseases

The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. The objective of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) is to help address the current shortage of physicians who conduct biomedical research by offering this career development opportunity.
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 12, 2020.

Metastasis Research Network (U54 Clinical Trial Not Allowed)
(RFA-CA-20-029) National Cancer Institute

The purpose of this Funding Opportunity Announcement (FOA) is to develop a comprehensive and cohesive understanding of cancer metastasis. Towards this goal, the National Cancer Institute (NCI) will support several U54 Specialized Centers that together will form the Metastasis Research Network (MetNet). Each MetNet Center should propose an overarching scientific theme that will be pursued through two or three scientific inter- and multi-disciplinary basic research projects.
Application Receipt Date(s): September 28, 2020; May 28, 2021

Research Program Award (R35 Clinical Trial Optional)
(RFA-NS-20-030) National Institute of Neurological Disorders and Stroke

The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased freedom and flexibility to Program Directors (PDs)/Principal Investigators (PIs) to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor trainees, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI’s recent NINDS support.
Application Receipt Date(s): July 31, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

PAR-19-207 Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)

National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this IC Name R25 program is to support educational activities that complement and/or foster a better understanding of biomedical, behavioral and clinical research and its implications.

Application due dates: August 11, 2020, November 17, 2020, March 15, 2021, August 10, 2021, November 15, 2021, March 15, 2022, August 10, 2022.

PAR-18-746 NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)

National Institute on Drug Abuse (NIDA)

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.

Application due date: June 30, 2020

RFA-MH-20-120 BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)

National Institute of Mental Health (NIMH), National Eye Institute (NEI), National Institute on Aging (NIA) National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS)

National Center for Complementary and Integrative Health (NCCIH)

The goal of this FOA is to promote studies that will significantly advance new discoveries and accelerate the pace of research of the BRAIN Initiative through harnessing the big data and machine learning opportunities. Awardees are expected to enhance the value of existing data, improve the overall data integration and analysis capability, and strengthen the statistical power and rigor and reproducibility of BRAIN Initiative related data.

Application due dates: September 6, 2019, June 11, 2020, and February 26, 2021

PAR-19-368 Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional). National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute ( NCI ).

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Standard application due dates apply; first available due date for this opportunity is June 5, 2020.

PAR-18-490  NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed) National Institute of Neurological Disorders and Stroke (NINDS)

The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research.

Standard due dates apply with the following extension per NOT-NS-20-067: New Application Due Date: February 12, 2021, Resubmission Date: March 12, 2021. This funding opportunity announcement has been extended by one additional council round.

Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional) - The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (https://www.drugabuse.gov/funding/funding-priorities) or within the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031). Standard application due dates apply. The first standard due date for this FOA is June 16, 2020. https://grants.nih.gov/grants/guide/pa-files/PA-20-208.html

Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed) - The NIH Research Education Program (R25) supports research educational activities that complement other formal training programs in the mission areas of the NIH Institutes and Centers. The over-arching goals of the NIH R25 program are to: (1) complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs; (2) enhance the diversity of the biomedical, behavioral and clinical research workforce; (3) help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences; and (4) foster a better understanding of biomedical, behavioral and clinical research and its implications.

The over-arching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. This FOA will support creative educational activities with a primary focus on Outreach. Specifically, this FOA will support projects designed to engage practicing health care professionals in education about current and emerging knowledge derived from scientific research on the neurobiology, epidemiology, prevention, and/or treatment of alcohol and other substance use disorders and related health conditions. Letter of Intent Due: July 11, 2020. Application Due: August 11, 2020. https://grants.nih.gov/grants/guide/pa-files/PAR-19-207.html

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) - The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers. Application due: May 7, 2023. https://grants.nih.gov/grants/guide/pa-files/PA-20-207.html

RFA-AI-20-009 Three-Dimensional (3D) Human Biomimetics for Infectious Diseases (U19 Clinical Trial Not Allowed). National Institute of Allergy and Infectious Diseases (NIAID)

The purpose of this funding opportunity announcement (FOA) is to solicit applications for a three-dimensional (3D) Human Biomimetics for Infectious Diseases Cooperative Research Centers (Biomimetics CRCs) program.  Applications are due May 29, 2020.

PAR-19-368 Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional). National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute ( NCI ).

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Standard application due dates apply; first available due date for this opportunity is June 5, 2020.

PAR-20-073 “National Dental Practice-Based Research Network Infrastructure Access (X01 Clinical Trial Not Allowed) National Institute of Dental and Craniofacial Research (NIDCR)

The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple clinical studies. This Funding Opportunity Announcement (FOA) is seeking applications for small developmental/exploratory, feasibility (pilot), and/or survey studies of practitioners and/or patients to be conducted in the National Dental PBRN.

Application due dates: September 1, 2020, September 1, 2021, and September 1, 2022.

PAR-20-093 - Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) National Institute of Mental Health (NIMH)

The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field.

Application due date: July 9, 2020

PAR-18-490 NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)  National Institute of Neurological Disorders and Stroke (NINDS)

The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research.

Standard due dates apply with the following extension per NOT-NS-20-067: New Application Due Date: February 12, 2021, Resubmission Date: March 12, 2021. This funding opportunity announcement has been extended by one additional council round.

PAR-19-373 Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Clinical Trials Not Allowed) and

PAR-19-384 Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Basic Experimental Studies with Humans Required)

NIH Basic Behavioral and Social Science Opportunity Network (OPPNET), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), and National Cancer Institute (NCI)

These funding opportunity announcements (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing.

Application due dates: June 8, 2020; March 17, 2021

NINDS Institutional Research Training Program (T32)

https://grants.nih.gov/grants/guide/pa-files/PAR-19-211.html

The purpose of this FOA is to provide support for institutional research training programs in areas relevant to the NINDS mission. These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to neuroscience research.

Application Due Dates: June 29, 2020; May 26, 2021, by 5:00 PM

PA-19-091 -NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) and

PA-19-092 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.”  Standard Application due dates apply

RFA-CA-20-027Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional) and

National Cancer Institute (NCI)

Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)

Through these Funding Opportunity Announcements (FOA), the NCI intends to support research projects that improve the care and/or quality of life for childhood, and adolescent young adult (AYA) cancer survivors. Application Deadlines for both opportunities:  October 1, 2020 or July 30, 2021.

PAR-18-538 Basic and Translation Research on Decision Making in Aging and Alzheimer's Disease (R21 - Clinical Trial Optional) and

PAR-18-544 Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01 - Clinical Trial Optional) 

National Institute on Aging (NIA)

This funding opportunity announcement (FOA) invites applications for basic research to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal aging and Alzheimer's disease (AD). Research is sought that will characterize the extent to which basic behavioral and neural processes involved in decision making are differentially impacted in normal aging and AD, investigate the influence of social factors on decision making, and investigate the decision-making factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse.

Revised Application Deadline for both opportunities: July 8, 2020

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
(PA-20-166) The National Institutes of Health (NIH) and the Center for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from underrepresented backgrounds, including those from groups that have been shown to be nationally underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project.  Administrative supplements must support work within the scope of the original project.

Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)
(PA-20-172)  The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
(RFA-RM-20-019) The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.

Notice of Special Interest (NOSI): Cannabis, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults
(NOT-DA-20-014)
National Institute on Drug Abuse

The goal of this funding is to conduct rigorous research on cannabis and potentially addictive, psychoactive prescription drug use (specifically opioids and benzodiazepine) in older adults. This program will focus on two distinct older adult populations (over the age of 50): (1) individuals with earlier use onset of cannabis and the specified drug classes who are now entering older age, or (2) individuals who initiate use of cannabis and the specified drug classes after the age of 50. Insights gained from this initiative have the potential to inform the public and health care systems regarding use of cannabis and prescription opioids and benzodiazepines in older populations.

*This funding opportunity is available through the following FOA.  Standard due dates for the FOA’s apply.

PA-19-055 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
PA-19-056 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-19-091 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
PA-19-052: NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-19-092: NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
PA-19-053: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-19-054: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)
(PA-20-173) and

Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)
(PA-20-174)
National Institutes of Health
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Standard dates apply.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

Notice of Special Interest: Promoting Research on Mechanisms of Pathogenesis and Pathophysiology of Atypical Femoral Fracture (AFF) and Osteonecrosis of the Jaw (ONJ)
(NOT-AR-21-006)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute on Aging
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health

Release Date: April 15, 2020
First Available Due Date: June 05, 2020

Related Opportunities

  • PA-19-056: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-19-053: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

Utilizing Cohort Studies to Address Health Outcomes in Cancer Survivors (UG3/UH3 Clinical Trial Not Allowed) 

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors (i.e., from diagnosis to the end of life). This FOA intends to support research that requires the creation of a new prospective cohort study that addresses a gap in knowledge pertaining to the health of cancer survivors. Applications must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or understudied populations of cancer survivors with disparities.  Application due: July 7, 2020.  https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-030.html

Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01 Clinical Trial Optional) (PAR-20-156) National Institute on Aging Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 5, 2020.

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) (PAR-20-157) National Institute of Mental Health Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 5, 2020.

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) (PAR-20-159) National Institute of Mental Health Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 16, 2020.

Pre-Solicitation Notice: Immunology Quality Assessment (IQA) Program, RFP: 75N93020R00007

(NOT-AI-20-042)

National Institute of Allergy and Infectious Diseases

Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders

(NOT-DA-20-046)

National Institute on Drug Abuse

Release Date: April 7, 2020
First Available Due Date: June 05, 2020

NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)

(RFA-MH-20-525)

National Institute of Mental Health

Application Receipt Date(s): June 20, 2020; June 20, 2021; June 20, 2022 No late applications will be accepted for this Funding Opportunity Announcement

Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)

(PAR-20-117)

National Institute of General Medical Sciences

Application Receipt Date(s): October 2, 2020; October 4, 2021; October 3, 2022

Maximizing Investigators Research Award (MIRA) (R35 - Clinical Trial Optional)

https://grants.nih.gov/grants/guide/pa-files/PAR-19-367.html

(PAR-19-367)

National Institute of General Medical Sciences

Application Receipt Date(s): May 18, 2020; January 19, 2021; May 17, 2021; January 18, 2022, May 17, 2022

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)

(PAR-20-118)

National Institute of Mental Health

National Institute on Alcohol Abuse and Alcoholism

National Institute on Drug Abuse

Application Receipt Date(s): July 27, 2020; November 25, 2020; March 25, 2021; July 26, 2021; November 26, 2021; March 25, 2022  

NIH Center Opportunities:

Intellectual and Developmental Disabilities Reserch Centers [IDDRC] FY 2021 (P50 Clinical Trial Optional) (RFA-HD-21-009) Eunice Kennedy Shriver National Institute of Child Health and Human Development Application Receipt Date(s): August 14, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

P50 Specialized Center: NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)

Application Deadlines:  September 25, 2020; September 25, 2021, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDA’s mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields.